Selected Publications
Liu A, Smith K, Kumar R, Paul L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P, Boop FA, Stewart CF, Harreld JH; Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell Nov 8;39(11):1519-1530.e4, 2021.
Ali JS, Ashford J, Swain MA, Harder LL, Carlson-Green BL, Miller JM, Wallace J, Kaner RJ, Billups CA, Onar-Thomas A, Merchant TE, Gajjar A, Conklin HA. Predictors of Cognitive Performance among Infants Treated for Brain Tumors: Findings from a Multisite, Prospective, Longitudinal Trial. JCO July 20;39(21):2350-2358, 2021.
Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol Mar 1;39(7):822-835, 2021.
Kumar R, Smith KS, Robinson GW, Deng M, Orr BA, Anthony PYL, Lin T, Billups C, Terhune C, Dhall G, Kleese L, Bowers D, Chintagumpala M, Leary S, Nazarian J, McLendon R, Packer R, Dunham C, Hukin J, Fouladi M, Faria C, Pimentel J, Walter A, Jabado N, Fontebasso A, Cho J, Perreault S, Croul S, Zapotocky Z, Sumerauer D, Hawkins C, Bouffet E, Tabori U, Taylor M, Pfister SM, Onar-Thomas A, Korshunov A, Gajjar A, Jones DTW, Ramaswamy V, Northcott PA. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology 39(7):807-821, 2021.
Baxter PA, Su JM, Onar Thomas A, Billups C, Li XN, Poussaint TY, Smith E, Thompson PA, Adesina A, Ansell P, Giranda VL, Paulino A, Kilburn L, Quaddoumi I, Broniscer A, Blaney SM, Dunkel I, Fouladi M. A Phase I/II Study of Veliparib (ABT-888), an oral Poly(ADP-ribose) Polymerase Inhibitor with Concurrent Radiation Therapy, Followed by Veliparib and Temozolomide in Children with Newly Diagnosed Pontine Glioma (DIPG): A Pediatric Brain Tumor Consortium Study. Neuro Oncol Jun 9;22(6):875-885, 2020.
Lafay-Cousin L, Strother D, Bouffet E, Hawkins C, Eberhart C, Horbinski C, Rudneva V, Heier L, Mark Souweidane MM, Williams-Hughes C, Onar-Thomas A, Billups A, Fouladi M, Northcott P, Gajjar A, Robinson G. A Phase II Study For Non Metastatic Desmoplastic Medulloblastoma In Children < 4 Years of Age, A Report of the Children's Oncology Group. J Clin Oncol Jan 20;38(3):223-231, 2020. PMID: 31774708
Fangusaro J, Wu S, MacDonald S, Murphy E, Shaw D, Bartels U, Khatua S, Williams-Hughes C, Souweidane M, Lu SM, Morris D, Panigrahy A, Onar-Thomas A, Fouladi M, Gajjar A, Dhall G. Outcomes of a Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Non-Germinomatous Germ Cell Tumors: A Children's Oncology Group Study, ACNS1123. J Clin Oncol Dec 1;37(34):3283-3290, 2019.
Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Billups CA, Bowers DC, Bendel AE, Hassall T, Crawford JR, Partap S, Fisher PG, Tatevossian RG, Seah T, Qaddoumi IA, Vinitsky A, Armstrong GT, Sabin ND, Tinkle CL, Klimo P., Indelicato DJ, Boop FA, Merchant TE, Ellison DW, Gajjar A. Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. Neuro-Oncology Oct 9;21(10):1319-1330, 2019.
Renfro LA, Ji L, Piao J, Onar-Thomas A, Kairalla JA, Alonzo TA. Trial Design Challenges and Solutions for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group. JCO Precision Oncology in Special Series: Statistical Methods in Precision Oncology 3:1-13, 2019.
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn L, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman S, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, , Patay Z, Tamrazi B, Jones JY, Haque S, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ*, Fouladi M*. Selumetinib in Children with BRAF-Aberrant or Neurofibromatosis type 1-Associated Recurrent, Refractory or Progressive Low-Grade Glioma: a Multi-Center Phase II Trial. Lancet Oncol Jul;20(7):1011-102, 2019.
Olivier TW, Bass JK, Ashford JM, Beaulieu R, Scott SM, Schreiber JE, Palmer S, Mabbott DJ, Swain MA, Bonner M, Frank R, Chapeiski ML, Evankovich KD, Armstrong CL, Knight SJ, Wu S, Onar-Thomas A, Gajjar A, Conklin HM. Cognitive Implications of Ototoxicity in Pediatric Patients with Embryonal Brain Tumors. J Clin Oncol 37(18):1566-1575, 2019.
Smith SMC, Bianski BM, Orr BA, Harknett G, Onar-Thomas A, Merchant TE, Roussel MF, Tinkle CL. Preclinical Modeling of Image-Guided Craniospinal Irradiation for the Treatment of High-Risk Medulloblastoma. Int J Radiat Oncol Biol Phys Mar 1;103(3):728-737, 2019.
Robinson GW, Rudneva VA, Buchhalter I, Billups C, Waszak S, Smith K, Bowers DC, Bendel A, Fisher A, Partap S, Crawford J, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA. Risk-adapted therapy for young children with medulloblastoma (SJYC07): results and molecular analysis from a prospective, multicenter phase II trial. Lancet Oncology 19(6):768-784, 2018. PMID: 29778738, PMCID: PMC6078206.
Robinson GW, Kaste SC, Chemaitilly W, Bowers D, Laughton S, Smith A, Gottardo N, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A. Irreversible Growth Plate Fusions in Children with Medulloblastoma Treated with Targeted Hedgehog Pathway Inhibitor. Oncotarget Sep 19; 8(41):69295–69302, 2017.
Zhu L, Poppleton Finkelstein D, Shi L, Wang M, Terrada DL, Wang K, Utley S, Pounds S, Neale J, Ellison DW, Onar-Thomas A*, Gilbertson1 RJ*. Multi-organ mapping of cancer risk. Cell 166(5):1132-1146.e7, 2016. (* Co-corresponding author).
Bass JK, Hua CH, Huang J, Onar-Thomas A, Ness KN, Jones S, White S, Bhagat SP, Chang KW, Merchant TE. Hearing loss in patients who received cranial radiation therapy for childhood cancer. Journal of Clinical Oncology Apr 10;34(11):1248-55, 2016.
Murugesan M, Currle DS, Eden C, Thiruvenkatam R, Boulos N, Dapper J, Kranenburg TA, Neale G, Olsen S, Finkelstein D, Wright K, Gupta G, Ellison DW, Onar-Thomas A, Gilbertson RJ. In vivo oncogenomics screen identifies novel ependymoma oncogenes and tumor suppressor genes within large chromosomal alterations. Nature Genetics Aug;47(8):878-887, 2015.
Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer R, Goldman S, Prados M, Desjardins A, Chingtagumpala M, Tabeke N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart C, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib Exerts Targeted Efficacy Against Recurrent SHH-Subgroup Medulloblastoma: Results from Phase II Pediatric Brain Tumor Consortium Studies – PBTC-025B and PBTC-032. Journal of Clinical Oncology 20;33(24):2646-54, 2015.
Xu H, Robinson GW, Huang J, Lim JYS, Bass J, Broniscer A, Chingtagumpala M, Bouffet E, Gururangan S, Hassall T, Fisher M, Cohn R, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ. Common Variants in ACYP2 Influence the Susceptibility to Cisplatin-induced Hearing Loss. Nature Genetics Mar;47(3):263-6, 2015.
Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol Oct 20;29(30):3999-4006, 2011.
Onar-Thomas A, Xiong Z. A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials. Contemp Clin Trials May;31(3):259-70, 2010. PubMed PMID: 20298812; PubMed Central PMCID: PMC2863035
Last update: January 2022